Sun Pharmaceutical Industries Ltd reported robust financial growth for the second quarter of fiscal year 2025, posting a 28% year-over-year (YoY) increase in net profit, reaching ₹3,040.16 crore. This is a marked improvement from ₹23,755.1 crore in the corresponding quarter last year, with a 7.2% sequential increase in profit.
The company’s revenue from operations saw a solid increase, climbing by nearly 10.5% YoY to ₹13,264.22 crore, compared to ₹12,003.11 crore in Q2FY24. Sun Pharma’s shares reflected this positive momentum, closing 2.24% higher at ₹1,902 on the BSE, buoyed by technical indicators and an upward trend highlighted by equity analysts.
EBITDA surged by 24% YoY, reaching ₹3,939 crore, with an improved EBITDA margin of 29.6%. Notably, domestic formulation sales rose by 11% to ₹4,265 crore, accounting for 32% of the company’s total sales.
The US market contributed significantly, with formulation sales rising 20% YoY to $517 million, or 33% of total sales, while sales in emerging markets grew 3.2% YoY to $293 million. Conversely, sales in Rest of World markets saw a minor 3% decrease, reaching $199 million.
The Active Pharmaceutical Ingredients (API) segment reported a 7% growth in external sales, totaling ₹534 crore, benefiting from the strategic focus on vertical integration for a stable supply chain. R&D investment accounted for 6% of sales, totaling ₹792.9 crore, underscoring Sun Pharma’s commitment to expanding its specialty pipeline. This included the FDA’s recent approval of Leqselvi for alopecia areata and a new partnership with Philogen to commercialize Fibromun, pending approval.
With these developments, Sun Pharma strengthens its foothold in the specialty sector, particularly within dermatology, aligning with its strategy to leverage financial strength for continued pipeline expansion.
Information sourced from [https://www.livemint.com/market/stock-market-news/muhurat-trading-2024-date-time-other-details-you-must-know-this-diwali-samvat-2081-11730365039730.html] for reference.
Photo Source: https://www.instagram.com/sunpharma_live/
